EVITA is a multicentric Latin-American prospective cohort on chronic hypersensitivity pneumonitis. EVITA's objective is to identify phenotypes and/or endotypes associated with different disease trajectories measured primarily by forced vital capacity (FVC) during a 24 month follow-up period. Other secondary measures of disease progression will also be investigated such as imaging, time to death or lung transplantation, and patient-reported outcomes
Who can participate
Age range18 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adult outpatient subjects (18 years old or older) that fulfill the 2020 ATS/JRS/ALAT diagnostic criteria of HP of at least moderate confidence (70% confidence or more).
✓. Willingness to undergo the evaluations proposed in this protocol
✓. HP diagnosis within the last 24 months
✓. Presence of radiological or histological fibrosis:
✓.a. Radiological fibrosis consists of unequivocal fine or coarse reticulation with architectural lung distortion and/or traction bronchiectasis and/or honeycomb.
✓.b. Unequivocal histopathological fibrosis evidenced on lung specimens
Exclusion criteria
✕. Pregnancy
✕. Presence of established connective tissue disease
✕. Severe comorbidity impacting on the respiratory system as judged by the attending physician (ex. congestive heart failure, neoplasm, post-COVID-19 sequelae)
✕. Use of supplemental oxygen at rest
✕. Dyspnea mMRC 4 (too breathless to leave the house or breathless when dressing or undressing)
✕. Unequivocal emphysematous pattern of HP on HRCT
✕. Unequivocal pleuro-parenchymal fibroelastosis on the HRCT
What they're measuring
1
Variation in Forced Vital Capacity (FVC) as a continuous variable